VRDN vs RAPT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VRDN Captures Institutional Edge (3โ1 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Viridian Therapeutics, Inc. Common Stock (VRDN) driven by superior Valuation, Growth & Margin, Options & Structure while RAPT counters with relative strength in Momentum & Technical. Fundamentally, VRDN trades at 1.0x Forward P/E with -1781.4% operating margin (-63.5% YoY revenue) versus RAPT at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, VRDN sits in SURGE (20th %ile IV; Dealer Gamma Walls on Pro) against RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VRDN | RAPT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.5B | $1.7B | Larger Scale | VRDN |
| Trailing P/E Ratio Valuation | 1.0x | N/M | Lower Multiple | VRDN |
| Forward P/E Ratio Valuation | 1.0x | N/M | Lower Multiple | VRDN |
| Revenue Growth (YoY) Growth | -63.5% | -100.0% | Higher Growth | VRDN |
| Operating Margin (TTM) Profitability | -1781.4% | 0.0% | Higher Margin | RAPT |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -83.7% | -85.4% | Higher ROE | VRDN |
| 52-Week Range Position Momentum | 81% ($13โ$34) | 100% ($1โ$58) | Stronger Trend | RAPT |
| Beta / 30D Volatility Risk Regime | 1.13ฮฒ ยท 65% Vol | -0.02ฮฒ ยท 2% Vol | Lower Realized Risk | RAPT |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 52.4 / 100 (HOLD) | Higher Composite | RAPT |